Pacira BioSciences(NASDAQ) PCRX

Pacira helps patients manage pain after surgery without using addictive opioid drugs. It makes long-lasting injections and cooling devices used by doctors in hospitals. These products help people recover more comfortably after medical procedures.

Beyond Opioids: The Product Mix

• EXPAREL: Long-acting local analgesic for surgery pain; represents 81% of net product sales in Q1 2026. An analgesic is a drug used to achieve relief from pain.
• ZILRETTA: Extended-release injection for osteoarthritis knee pain; accounts for 15% of net product sales in Q1 2026. Osteoarthritis is a common form of arthritis caused by the breakdown of joint cartilage.
• iovera system: Handheld device that uses cold temperatures to block pain signals in targeted nerves. This process, known as cryoanalgesia, provides long-acting drug-free pain control.
• HCAd Platform: Gene therapy technology used to deliver genetic medicines directly to specific areas of the body. HCAd stands for high-capacity adenovirus, a specific tool for transporting medical treatments into cells.

Strategic Steps and Purchases

• In February 2025, Pacira finished the acquisition of GQ Bio Therapeutics GmbH to gain a new gene therapy platform.
• The company added ZILRETTA to its portfolio in November 2021 by purchasing Flexion Therapeutics, Inc.
• Pacira expanded into drug-free pain control in April 2019 through the acquisition of MyoScience, Inc.
• In April 2025, the company settled a patent dispute with eVenus Pharmaceutical Laboratories, Inc. to manage the entry of generic competitors.

What Makes Pacira Different?

Pacira uses a proprietary drug delivery technology that wraps medicine in tiny fat-like particles called liposomes. This allows the drug to release slowly over time without changing its molecular structure. The company controls its own production for key products at its manufacturing facilities in San Diego and the United Kingdom.

The Financial Scoreboard

• Total revenues reached $177.4 million in Q1 2026, up 5% from Q1 2025.
• Operating income hit $6.9 million in Q1 2026, an increase of 246.8% over the previous year.
• Net income was $2.9 million in Q1 2026, compared to $4.8 million in Q1 2025.
• The company repurchased $50.4 million of its own shares during the three months ended March 31, 2026.
• Cash and cash equivalents totaled $144.3 million as of March 31, 2026.

Bottom Line

Pacira has evolved from a single-product business into a diversified provider of non-opioid pain and regenerative therapies. Its shift toward gene therapy and long-acting injections aims to reduce medical reliance on traditional opioid treatments.